About
Technology
Personalized Medicine
General Inquiries
Revolutionizing Cancer Treatment with Personalized Immunotherapy
Harnessing the power of your own immune system through cutting-edge autologous dendritic cell therapy to fight cancer with unprecedented precision using the safest type of cancer therapy known, autologous Dendritic Cells.
Start Your Journey
About Autodendrix
Autodendrix is at the forefront of personalized cancer immunotherapy, pioneering advanced autologous dendritic cell therapy solutions that transform the way we treat cancer. Our innovative approach leverages each patient's unique immune system to create targeted, effective treatments using Dendritic Cell Therapy, which, as a class, has an established safety record in humans.
Scientific Excellence
Built on decades of immunotherapy research and pre-clinical validation, our dendritic cell platform represents the next generation of cancer treatment.
Personalized Medicine
Each treatment is made using the patient's own cells for compatibility and a reduced risk of adverse reactions.
Safety First
Autologous DC therapy has been established as having a superior safety record in humans.
Our Technology
Dendritic cells are the "generals" of the immune system, orchestrating targeted responses against cancer cells. Our proprietary autologous platform harnesses these powerful immune commanders to create personalized cancer vaccines.
How Autologous Dendritic Cell Therapy Works
1.
Cell Collection
Cells are removed at a blood collection center, and your white blood cells are shipped overnight to the manufacturing lab.
2.
Ex Vivo Processing
In a 5-day process at the GMP-certified laboratory, your cells will become Dendritic Cells and matched with tumor protein fragments to prime killer T cells.
3.
Activation & Enhancement
The cells are activated and optimized to become highly effective at presenting cancer antigens to to T cells, giving them a 'License to Kill" tumors.
4.
Infusion of Cell Therapy
The enhanced dendritic cells are reintroduced to the patient, where they train the immune system to recognize and attack cancer cells.
Clinical Validation
FDA Precedent

Provenge (sipuleucel-T), the first FDA-approved dendritic cell therapy, demonstrated significant survival benefits in prostate cancer patients.

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t

Market Growth
The global dendritic cell therapy market is projected to reach $4.1 billion by 2034, growing at 12.8% CAGR.
https://www.researchnester.com/reports/dendritic-cell-cancer-vaccine-market/7885
Clinical Impact

Studies show Dendritic Cells lead to significant improvements in survival even in cancer types like glioma brain tumors resistant to other drugs:

https://pubmed.ncbi.nlm.nih.gov/36394838/

Dendritic Cells Reinvented
Our Dendritic Cell technology seeks to build on the historical safety record with improvements in tumor killing demonstrated in our upcoming clinical trials.
Compatibility
Using the patient's own cells greatly reduces the risk of immune rejection and graft-versus-host disease.
Targeted Precision
Our tumor antigen loading process is designed to trigger both new and recall memory responses to the patient's unique set of tumor protein targets.
Minimal Side Effects
Historically, Dendritic Cells are very safe, especially compared with cytotoxic chemotherapy and radiation methods.
Long-term Memory
Dendritic Cells can program long-term memory T cells. Autodentrix is designed to trigger short- and long-term killer cells with receptors for tumor protein targets to prevent recurrence and metastasis.
Targeted Treatment Applications
Solid Tumors
Dendritic Cells have been proven effective against solid tumors, including brain, lung, and breast.
Hematological
Promising results in blood cancers and lymphomas with improved survival outcomes.
https://pubmed.ncbi.nlm.nih.gov/31234526/
Recurrent Cases
Dendritic cells have been shown to reduce the chance of recurrence in some patients.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9406463/
Ready to Explore Personalized Cancer Treatment?
Learn more about our mission to make Dendritic cell therapy the treatment of choice for patients with a variety of solid and liquid tumors.
Contact Our Team Today
All consultations are confidential and HIPAA compliant. We're committed to providing you with the information you need to make informed decisions about your care.
© 2025 Autodendrix. Leading the future of personalized cancer immunotherapy.
Disclaimer: This website is for informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals before making any medical decisions. No drug can be promoted as safe or effective until confirming data from human trials has been validated by regulatory approval agencies. To learn more about the drug approval process, visit: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber
Advancing Precision Medicine • Personalized Cancer Care • Scientific Innovation